AR080747A1 - Proceso para preparar particulas de vehiculo para polvos secos para inhalacion - Google Patents
Proceso para preparar particulas de vehiculo para polvos secos para inhalacionInfo
- Publication number
- AR080747A1 AR080747A1 ARP110101070A ARP110101070A AR080747A1 AR 080747 A1 AR080747 A1 AR 080747A1 AR P110101070 A ARP110101070 A AR P110101070A AR P110101070 A ARP110101070 A AR P110101070A AR 080747 A1 AR080747 A1 AR 080747A1
- Authority
- AR
- Argentina
- Prior art keywords
- particles
- vehicle
- pharmaceutical composition
- inhalation
- bromide
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 12
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 7
- 239000011248 coating agent Substances 0.000 abstract 6
- 238000000576 coating method Methods 0.000 abstract 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 6
- 239000000843 powder Substances 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 3
- 239000008101 lactose Substances 0.000 abstract 3
- 235000019359 magnesium stearate Nutrition 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 abstract 1
- MDHKCIIEVIPVLU-JERHFGHZSA-M 4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 MDHKCIIEVIPVLU-JERHFGHZSA-M 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 abstract 1
- 229960005012 aclidinium bromide Drugs 0.000 abstract 1
- XLAKJQPTOJHYDR-QTQXQZBYSA-M aclidinium bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 XLAKJQPTOJHYDR-QTQXQZBYSA-M 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 229940092705 beclomethasone Drugs 0.000 abstract 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 238000005520 cutting process Methods 0.000 abstract 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 abstract 1
- 229960001469 fluticasone furoate Drugs 0.000 abstract 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 1
- 229960004078 indacaterol Drugs 0.000 abstract 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229960001361 ipratropium bromide Drugs 0.000 abstract 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 abstract 1
- 229950001768 milveterol Drugs 0.000 abstract 1
- 229960002744 mometasone furoate Drugs 0.000 abstract 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 abstract 1
- BMKINZUHKYLSKI-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[[(2r)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 abstract 1
- 229960004286 olodaterol Drugs 0.000 abstract 1
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 abstract 1
- 229960000797 oxitropium Drugs 0.000 abstract 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 abstract 1
- 229960002016 oxybutynin chloride Drugs 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229960004017 salmeterol Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960000257 tiotropium bromide Drugs 0.000 abstract 1
- 229960001530 trospium chloride Drugs 0.000 abstract 1
- 229960004026 vilanterol Drugs 0.000 abstract 1
- DAFYYTQWSAWIGS-DEOSSOPVSA-N vilanterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 DAFYYTQWSAWIGS-DEOSSOPVSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Proceso para preparar partículas de vehículo para usar en formulaciones en polvo seco para inhalacion, las partículas de vehículo que se pueden obtener mediante dicho proceso y las formulaciones farmacéuticas en polvo de las mismas. Reivindicacion 1: Un proceso para la preparacion de un vehículo para composiciones farmacéuticas en polvo para inhalacion, caracterizado porque el proceso comprende someter a partículas de lactosa, que tienen un diámetro de masa en el rango entre 30 y 1000 micrones a recubrimiento en seco con entre 0,1 y 1,3% de estearato de magnesio en peso del vehículo para proveer un recubrimiento superficial de las partículas de lactosa con dicho estearato de magnesio en una extension tal que las partículas recubiertas tienen más de 60% de recubrimiento superficial, en donde el paso de recubrimiento en seco se lleva a cabo en un granulador de alto esfuerzo de corte basado en el comportamiento de friccion a una velocidad de rotacion igual o mayor a 500 r.p.m., pero igual a o menor que 2500 r.p.m. Reivindicacion 8: Partículas de vehículo para una formulacion farmacéutica en polvo seco, caracterizadas porque dichas partículas de vehículo comprenden partículas de lactosa que tienen un diámetro de masa en el rango entre 30 y 1000 micrones recubiertas con entre 0,1 y 1,3% de estearato de magnesio en peso del vehículo a una extension tal que las partículas recubiertas tienen más de 60% de recubrimiento superficial, en donde dichas partículas de vehículo se pueden obtener mediante un proceso que comprende recubrimiento en seco en un granulador de alto esfuerzo de corte basado en el comportamiento de friccion a una velocidad de rotacion igual a o mayor que 500 r.p.m., pero igual a o menor que 2500 r.p.m. Reivindicacion 10: Una composicion farmacéutica en forma de polvo seco para inhalacion caracterizada porque comprende las partículas de vehículo de la reivindicacion 8 y uno o más ingredientes. Reivindicacion 11: La composicion farmacéutica de acuerdo a la reivindicacion 10, caracterizada porque el ingrediente activo comprende un agonista beta2 que se elige del grupo que consiste en salmeterol, formoterol, milveterol, vilanterol, olodaterol e indacaterol o una sal y/o solvato de los mismos. Reivindicacion 12: La composicion farmacéutica de acuerdo a la reivindicacion 10 u 11, caracterizada porque el ingrediente activo comprende un anticolinérgico que se elige del grupo que consiste en bromuro de tiotropio, bromuro de ipratropio, bromuro de oxitropio, cloruro de oxibutinina, bromuro de aclidinio, cloruro de trospio, bromuro de glicopirronio, GSK 573719 y GSK 1160274. Reivindicacion 13: La composicion farmacéutica de acuerdo a cualquiera de las reivindicaciones 10 a 12, caracterizada porque el ingrediente activo comprende un corticoesteroide que se elige del grupo que consiste en dipropionato de beclometasona, propionato de fluticasona, furoato de fluticasona, budesonide y furoato de mometasona. Reivindicacion 14: La composicion farmacéutica de acuerdo a cualquiera de las reivindicaciones 10 a 13, caracterizada porque el ingrediente activo comprende un inhibidor de fosfodiesterasa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10158951 | 2010-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080747A1 true AR080747A1 (es) | 2012-05-02 |
Family
ID=42790618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101070A AR080747A1 (es) | 2010-04-01 | 2011-03-31 | Proceso para preparar particulas de vehiculo para polvos secos para inhalacion |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8974831B2 (es) |
| EP (2) | EP2762133A1 (es) |
| JP (2) | JP5927175B2 (es) |
| KR (1) | KR101730684B1 (es) |
| CN (2) | CN102858326A (es) |
| AR (1) | AR080747A1 (es) |
| AU (1) | AU2011234751B2 (es) |
| BR (1) | BR112012024059B1 (es) |
| CA (1) | CA2794941C (es) |
| ES (1) | ES2675575T3 (es) |
| HK (1) | HK1204569A1 (es) |
| IL (1) | IL222154A (es) |
| MX (1) | MX336414B (es) |
| MY (1) | MY162391A (es) |
| PH (1) | PH12012501792A1 (es) |
| PL (1) | PL2552424T3 (es) |
| RU (1) | RU2585101C2 (es) |
| SG (1) | SG184352A1 (es) |
| TR (1) | TR201811349T4 (es) |
| TW (1) | TWI491417B (es) |
| UA (1) | UA110106C2 (es) |
| WO (1) | WO2011120779A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| SI3106149T1 (sl) | 2009-05-29 | 2020-07-31 | Pearl Therapeutics, Inc. | Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi |
| DK3527199T3 (da) * | 2012-01-25 | 2022-10-24 | Chiesi Farm Spa | Tørpulverformulering omfattende et kortikosteroid og et beta-adrenergikum til indgivelse via inhalation |
| BR112014025518B1 (pt) | 2012-04-13 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas |
| EP2666465A1 (en) * | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
| HK1215396A1 (zh) * | 2012-12-27 | 2016-08-26 | 微剂量治疗公司 | 用於施用奥昔布宁的方法和组合物 |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| KR102275904B1 (ko) * | 2013-07-11 | 2021-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제 |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| PL2897589T3 (pl) * | 2013-11-22 | 2018-06-29 | Teva Branded Pharmaceutical Products R & D, Inc. | Lek do inhalacji |
| SG11201700536XA (en) * | 2014-09-09 | 2017-02-27 | Vectura Ltd | Formulation comprising glycopyrrolate, method and apparatus |
| CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
| GB201500447D0 (en) * | 2015-01-12 | 2015-02-25 | Glaxosmithkline Ip Dev Ltd | Novel Combination Product |
| KR20160117069A (ko) * | 2015-03-31 | 2016-10-10 | 한미약품 주식회사 | 복합 활성성분의 안정성이 개선된 흡입용 캡슐제 |
| CN105012278B (zh) * | 2015-08-04 | 2017-12-29 | 广东省生物工程研究所（广州甘蔗糖业研究所） | 一种干粉吸入粉雾剂载体蔗糖及其制备方法 |
| CN114425049A (zh) * | 2016-07-04 | 2022-05-03 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的药物组合物所用的载体的制备方法 |
| TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
| US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| CN109200034A (zh) * | 2017-06-30 | 2019-01-15 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的组合物及其制备方法 |
| WO2019067708A1 (en) * | 2017-09-27 | 2019-04-04 | Teva Branded Pharmaceutical Products R&D, Inc. | METHOD FOR DECREASING PARTICLE SIZE |
| US11696895B2 (en) | 2017-12-28 | 2023-07-11 | Sumitomo Pharma Co., Ltd. | Fine particle coating (drug-containing hollow particle and method for manufacturing same) |
| JP7239604B2 (ja) | 2018-04-16 | 2023-03-14 | ツェティ，ユリア | 甲状腺ホルモンを含む吸入用の薬学的乾燥粉末組成物 |
| EP3833964B1 (en) | 2018-08-07 | 2023-07-26 | Norton (Waterford) Limited | Application of raman spectroscopy for the manufacture of inhalation powders |
| CN109745564A (zh) * | 2019-01-28 | 2019-05-14 | 上海方予健康医药科技有限公司 | 一种吸入干粉组合物的制备方法 |
| KR102669919B1 (ko) * | 2019-07-10 | 2024-05-28 | 한미약품 주식회사 | 흡입용 캡슐제 및 이의 제조방법 |
| KR102898819B1 (ko) | 2019-09-24 | 2025-12-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입용 건조 분말 제제를 위한 신규 담체 입자 |
| WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
| US20240033222A1 (en) | 2020-08-14 | 2024-02-01 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate |
| WO2022045995A1 (en) * | 2020-08-28 | 2022-03-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
| WO2023069028A1 (en) * | 2021-10-20 | 2023-04-27 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
| CA3268243A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR |
| WO2024133905A1 (de) | 2022-12-22 | 2024-06-27 | Stada Arzneimittel Ag | Pharmazeutische zusammensetzung zur behandlung von copd |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT347054B (de) | 1973-09-29 | 1978-12-11 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von neuen nonapeptidamid-derivaten |
| NL7611963A (nl) | 1975-10-29 | 1977-05-03 | Parke Davis & Co | Werkwijze voor het bereiden van nieuwe nonapep- tiden. |
| US4124577A (en) | 1977-06-13 | 1978-11-07 | Warner-Lambert | Nonapeptides and methods for their production |
| US4317815A (en) | 1979-06-13 | 1982-03-02 | Coy David Howard | LH-RH Antagonists |
| US5110904A (en) | 1989-08-07 | 1992-05-05 | Abbott Laboratories | Lhrh analogs |
| CA2347856C (en) * | 1998-11-13 | 2009-02-17 | Jagotec Ag | Dry powder for inhalation |
| PL196951B1 (pl) | 1999-03-05 | 2008-02-29 | Chiesi Farma Spa | Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika |
| IT1309592B1 (it) | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| ITMI991582A1 (it) * | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| JP4380988B2 (ja) * | 2000-11-30 | 2009-12-09 | ヴェクトゥラ リミテッド | 医薬組成物に用いられる粒子の製造方法 |
| PT1386630E (pt) | 2002-07-31 | 2006-09-29 | Chiesi Farma Spa | Inalador em po |
| AU2003259910A1 (en) * | 2002-08-14 | 2004-03-03 | E.I. Du Pont De Nemours And Company | Process for coating a pharmaceutical particle |
| US20070065372A1 (en) | 2003-02-21 | 2007-03-22 | Robert Price | Process for the production of particles |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| GB0705159D0 (en) | 2007-03-19 | 2007-04-25 | Prosonix Ltd | Process for making crystals |
| GB0711680D0 (en) | 2007-06-18 | 2007-07-25 | Prosonix Ltd | Process |
| GB0712316D0 (en) * | 2007-06-26 | 2007-08-01 | Entripneur Ltd | A novel powder and its method of manufacture |
| BRPI0819259A2 (pt) | 2007-11-07 | 2019-10-01 | Astrazeneca Ab | formulações de pó seco compreendendo derivados do ácido ascórbico. |
| EP2080508A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
| EP2321023B1 (en) | 2008-07-18 | 2016-06-15 | Prosonix Limited | Process for improving crystallinity of fluticasone particles |
| WO2010097114A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Novel combination of therapeutic agents |
| EP2621494B1 (en) | 2010-09-30 | 2018-11-07 | Chiesi Farmaceutici S.p.A. | Use of magnesium stearate in dry powder formulations for inhalation |
-
2011
- 2011-03-11 BR BR112012024059-5A patent/BR112012024059B1/pt active IP Right Grant
- 2011-03-11 WO PCT/EP2011/053695 patent/WO2011120779A1/en not_active Ceased
- 2011-03-11 TR TR2018/11349T patent/TR201811349T4/tr unknown
- 2011-03-11 EP EP14161931.2A patent/EP2762133A1/en not_active Withdrawn
- 2011-03-11 CA CA2794941A patent/CA2794941C/en active Active
- 2011-03-11 ES ES11712196.2T patent/ES2675575T3/es active Active
- 2011-03-11 AU AU2011234751A patent/AU2011234751B2/en active Active
- 2011-03-11 JP JP2013501717A patent/JP5927175B2/ja active Active
- 2011-03-11 PH PH1/2012/501792A patent/PH12012501792A1/en unknown
- 2011-03-11 CN CN2011800163499A patent/CN102858326A/zh active Pending
- 2011-03-11 CN CN201410433301.3A patent/CN104257610A/zh active Pending
- 2011-03-11 KR KR1020127025537A patent/KR101730684B1/ko active Active
- 2011-03-11 SG SG2012072476A patent/SG184352A1/en unknown
- 2011-03-11 MX MX2012010914A patent/MX336414B/es unknown
- 2011-03-11 EP EP11712196.2A patent/EP2552424B1/en active Active
- 2011-03-11 RU RU2012142295/15A patent/RU2585101C2/ru active
- 2011-03-11 MY MYPI2012004309A patent/MY162391A/en unknown
- 2011-03-11 PL PL11712196T patent/PL2552424T3/pl unknown
- 2011-03-31 TW TW100111216A patent/TWI491417B/zh active
- 2011-03-31 AR ARP110101070A patent/AR080747A1/es unknown
- 2011-04-01 US US13/078,057 patent/US8974831B2/en active Active
- 2011-11-03 UA UAA201211276A patent/UA110106C2/ru unknown
-
2012
- 2012-09-27 IL IL222154A patent/IL222154A/en active IP Right Grant
-
2013
- 2013-01-29 HK HK15105170.4A patent/HK1204569A1/xx unknown
-
2015
- 2015-01-28 US US14/607,289 patent/US9445999B2/en active Active
- 2015-07-10 JP JP2015138861A patent/JP6162181B2/ja active Active
-
2016
- 2016-08-19 US US15/241,516 patent/US20160354314A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080747A1 (es) | Proceso para preparar particulas de vehiculo para polvos secos para inhalacion | |
| SI2560611T1 (en) | A process for preparing particles with reduced electrostatic charges | |
| HRP20191686T4 (hr) | Mikronizirane čestice aktivnih tvari za praškaste formulacije za inhalaciju u niskim dozama | |
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| AU2013336492A1 (en) | Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane | |
| JP2013056928A5 (es) | ||
| HRP20241300T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| JP2019501876A5 (es) | ||
| AR070834A1 (es) | Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios | |
| MY182861A (en) | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination | |
| CA2827045A1 (en) | Compositions of glycopyrrolate and a beta2-agonist | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| JP2015511241A5 (es) | ||
| HRP20220929T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje astme | |
| HK1215388A1 (zh) | 可吸入药用组合物和含有该药用组合物的吸入器装置 | |
| IN2014DN11257A (es) | ||
| ES2609821T3 (es) | Inhaladores de polvo seco que comprenden un vehículo distinto de lactosa y un componente ternario | |
| HRP20211600T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| MY174090A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| HRP20200571T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| MX375427B (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion | |
| AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
| JP2017057223A5 (es) | ||
| CA2845258C (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease |